Compare MPA & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPA | UNCY |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.3M | 150.1M |
| IPO Year | 1994 | 2021 |
| Metric | MPA | UNCY |
|---|---|---|
| Price | $10.67 | $5.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.67 |
| AVG Volume (30 Days) | 20.9K | ★ 686.8K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $582.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.60 | $3.72 |
| 52 Week High | $11.87 | $8.74 |
| Indicator | MPA | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 23.07 | 42.18 |
| Support Level | N/A | $4.81 |
| Resistance Level | $11.47 | $5.86 |
| Average True Range (ATR) | 0.11 | 0.21 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 13.91 | 3.76 |
Blackrock Muniyield Pennsylvania Quality Fund is a closed-end fund with an investment objective to provide shareholders with as high a level of current income exempt from U.S. federal and Pennsylvania income taxes as is consistent with its investment policies and prudent investment management. The Fund seeks to achieve its investment objective by investing, as a fundamental policy, at least 80% of an aggregate of the Fund's net assets and the proceeds of any borrowings for investment purposes, in a portfolio of municipal obligations issued by or on behalf of the State of Pennsylvania, its political subdivisions, agencies, and instrumentalities and by other qualifying issuers.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.